Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
60 Degrees Pharma licenses FSU technology to purify castanospermine and begins U.S. regulatory steps for non-Rx Australian Chestnut Extract.
-
60 Degrees Pharma partners with Runway Health to give international travelers direct telehealth access to once-weekly ARAKODA for malaria prevention.
-
60 DEGREES PHARMACEUTICALS, INC. ANNOUNCES APPROVAL OF REVERSE STOCK SPLIT RATIO
-
Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.
-
60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials
-
60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.
-
60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.
-
First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.
-
60 Degrees Pharma unveils “B-FREE” Phase 2 trial for chronic babesiosis, engaging patients in naming and supporting Lyme research groups.
-
60 Degrees Pharma (Nasdaq: SXTP) CEO Dr. Geoff Dow to present at HCW Conference Tuesday, Sept 9, 3:30 PM ET. Live webcast link available.